Financial Data and Key Metrics Changes - In 2025, rental revenue totaled $164.3 million, a 14% increase year-over-year, while total revenue reached $172.3 million, up approximately 10% compared to 2024 [13] - Adjusted EBITDA for the fourth quarter was $21.2 million, and for the full year, it was $81 million, both record figures for the company [6][19] - Net income for 2025 was $19.9 million, or $1.57 per diluted share, marking record performance [15] Business Line Data and Key Metrics Changes - Rented horsepower increased to approximately 563,000 by year-end 2025, a 14% increase over the prior year, with fleet utilization reaching 84.9% [5] - Rental revenue in the fourth quarter was $44.3 million, reflecting a 16% year-over-year increase due to fleet expansion and strong demand for large horsepower compression units [5] Market Data and Key Metrics Changes - Demand for natural gas compression remains strong, driven by domestic oil production, particularly in liquid-rich basins like the Permian [9] - Structural tailwinds include increasing LNG export capacity and growing electricity consumption from data centers and AI-related infrastructure [9][22] Company Strategy and Development Direction - The company is focused on large horsepower and electric units, which generate higher returns and longer contract durations [8] - NGS is committed to a capital allocation framework that combines organic growth, shareholder returns through dividends and share repurchases, and disciplined evaluation of strategic M&A opportunities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth and market share expansion, expecting Adjusted EBITDA guidance for 2026 to be between $90.5 million and $95.5 million [19][22] - The company is monitoring geopolitical developments and their potential impact on global oil markets and U.S. production activity [9] Other Important Information - The company initiated a return of capital program in 2025, returning approximately $2.6 million to shareholders in the second half of the year [7] - Capital expenditures for 2025 totaled $121.5 million, with $109.8 million allocated for growth capital expenditures [17] Q&A Session Summary Question: Guidance on Adjusted Rental Gross Margin - Management did not provide specific guidance but expects modest uplift from the 60.6% margin achieved in 2025 [24] Question: Lead Times for Equipment - Lead times for large horsepower units have extended significantly, particularly for high-end models, but lower horsepower units have not seen significant changes [25][26] Question: Competitive Environment and Pricing - The competitive landscape is evolving, and while lead times are increasing, the company has sufficient units to meet customer needs [31] Question: Maintenance Capital Expenditures - Maintenance capital expenditures are expected to gradually increase due to the significant fleet horsepower growth over the past five years [59] Question: Discretionary Cash Flow and Return of Capital - Management acknowledged the importance of a consistent and increasing dividend but did not provide specific guidance for future returns of capital [45]

Abeona Therapeutics (NasdaqCM:ABEO) Q4 2025 Earnings call March 17, 2026 08:30 AM ET Company ParticipantsBrian Kevany - CTOJoe Vazzano - CFOMadhav Vasanthavada - Chief Commercial OfficerVish Seshadri - CEOConference Call ParticipantsDavid Bautz - Senior Biotech AnalystJeff Jones - Managing Director and Senior AnalystKristen Kluska - Equity Research AnalystMaury Raycroft - Equity Research AnalystRam Selvaraju - Managing Director and Senior Healthcare Equity Research AnalystStephen Willey - Managing Director ...

Financial Data and Key Metrics Changes - In Q4 2025, rental revenue reached $44.3 million, a 16% year-over-year increase, while full-year rental revenue totaled $164.3 million, up 14% from the previous year [5][12] - Adjusted EBITDA for Q4 was $21.2 million, and for the full year, it was $81 million, both record figures for the company [5][12] - Net income for 2025 was $19.9 million, or $1.57 per diluted share, marking a record performance [15] Business Line Data and Key Metrics Changes - Rented horsepower increased to approximately 563,000 by year-end 2025, a 14% increase over the prior year, with fleet utilization reaching 84.9% [5][12] - Adjusted Rental Gross Margin for the full year was $99.6 million, reflecting a 14% year-over-year increase [13] Market Data and Key Metrics Changes - Demand for natural gas compression remains strong, driven by domestic oil production, particularly in liquid-rich basins like the Permian [8] - The company expects structural tailwinds from increasing LNG export capacity and growing electricity consumption from data centers and AI-related infrastructure [21][22] Company Strategy and Development Direction - The company is focused on fleet expansion, particularly in large horsepower and electric units, which generate higher returns and longer contract durations [7] - NGS initiated a return of capital program in 2025, including a dividend program that returned approximately $2.6 million to shareholders [6][17] - The company is committed to a disciplined capital allocation framework that includes organic growth, shareholder returns, and strategic M&A opportunities [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive further improvements and increase shareholder value, citing strong execution and market share gains [4] - The company anticipates continued organic growth in 2026, driven by large horsepower deployments and sustained industry demand for compression services [19] Other Important Information - The company recorded a $2.6 million non-cash impairment charge related to its Midland headquarters property [15] - Capital expenditures for 2025 totaled $121.5 million, with approximately $109.8 million allocated to growth capital expenditures for new large horsepower compression units [17] Q&A Session Summary Question: Guidance on large horsepower and electric motor drive assets' impact on rental gross margins - Management did not provide specific guidance on Adjusted Rental Gross Margin but expects modest uplift from the 60.6% figure in 2025 [24] Question: Lead times for large horsepower units and current bottlenecks - Lead times for high-end large horsepower units have extended beyond 100 weeks, while lower horsepower units have not seen significant changes [25][26] Question: Competitive environment and pricing due to delays in large horsepower units - The competitive landscape is evolving, and while lead times for high horsepower units are long, the company has sufficient units to meet customer needs [32] Question: Opportunities in midstream and pricing dynamics - The company is seeing quoting activity in midstream but has not yet won contracts in that area; they believe they can penetrate this market with their technology and service [38][42] Question: Return of capital and dividend strategy moving forward - Management understands shareholders' desire for a consistent and increasing dividend but did not provide specific guidance for 2026 [46] Question: Maintenance capital expenditures and their trajectory - Maintenance capital expenditures are expected to gradually increase due to the significant fleet horsepower growth over the past five years [61]

Financial Data and Key Metrics Changes - Discretionary assets under management (AUM) decreased by 1.2% in Q4 2025 from $24.3 billion to $24 billion, while total discretionary AUM increased by 3% for the year from $23.3 billion to $24 billion [3][4] - Total AUM decreased by 1.6% in Q4 to $37 billion but increased by 2% year-over-year from $36.5 billion [4][10] - Revenue for Q4 was $32 million, with a reported consolidated net loss of $0.1 million [10][14] - Adjusted EBITDA for Q4 was approximately $2.9 million, representing 8.9% of revenue [11] - For the full year, revenue increased by $1.7 million or 1.3%, while expenses increased by $10 million or 9.4% [12][13] Business Line Data and Key Metrics Changes - Organic new client accounts added in Q4 totaled $124.5 million, bringing the full year total to $688.3 million, indicating strong client acquisition [3] - Compensation and benefits expense for the full year was $83.9 million, representing 67% of revenue, up from 62% in 2024 [7][13] Market Data and Key Metrics Changes - The firm ranked 6th in Nasdaq eVestment's Q4 2025 brand awareness rankings among mid-sized firms, indicating growing recognition in institutional capabilities [6] - The firm is expanding its international business development efforts with professionals in London and Australia, and is nearing completion of an Australian investment trust and a UCITS vehicle in Europe [6] Company Strategy and Development Direction - Silvercrest is making significant strategic investments to promote growth across multiple fronts, focusing on intellectual capital and headcount [5] - The firm is adjusting its interim compensation ratio to match investments in business growth, expecting it to remain elevated for the foreseeable future [7] - The company is actively pursuing regulatory approval to operate in Europe through a new Dublin office, which is expected to be completed in Q2 2026 [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term vision and investment plans, anticipating that these will bear fruit with patience [43] - The firm is optimistic about the potential for significant AUM growth in global and international strategies, currently holding over $2 billion in these areas [21][25] Other Important Information - Total assets at the end of 2025 were approximately $166.6 million, down from $194.4 million at the end of 2024 [14] - Cash and cash equivalents at the end of 2025 were $44.1 million, compared to $68.6 million at the end of 2024 [15] Q&A Session Summary Question: Current AUM in global and international strategies and future growth potential - The firm currently has over $2 billion in global and international strategies, with strong performance and a robust pipeline expected to yield significant flows in 2026 [21][25] Question: Future compensation ratio expectations - The compensation ratio is expected to remain elevated due to ongoing hiring and investment in growth, with historical ratios around 54%-56% [30][31] Question: Thoughts on future buybacks and share count - Management indicated that further buybacks will be considered, and they aim to offset any shares given to employees to maintain a declining share count [37][38]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] - EBITDA for Q4 2025 was negative $4.3 million, an improvement from negative $11 million in the prior year [20] - Cash provided by operations in Q4 was positive $0.9 million, marking a significant improvement from negative cash flow earlier in the year [21] Business Line Data and Key Metrics Changes - NeuroStar business revenue, including system and treatment session revenue, was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a pro forma increase of 6% compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [9] - The expansion of TRICARE West coverage for TMS therapy to include adolescents aged 15 and older is a significant development for military families [13] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [26][28] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [28][29] - The company is focused on operational efficiency and expects to reduce operating expenses to less than $100 million by Q4 2026 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive revenue growth and achieve sustainable operating cash flow, with expectations for positive cash flow in the second half of 2026 [25] - The company acknowledges seasonality impacts on revenue, particularly in Q1, and is adapting its strategies accordingly [55][56] - Management highlighted the importance of maintaining strong relationships with primary care physicians and enhancing patient access to treatments [26] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026, indicating a leadership transition [5] - The company has made significant progress in integrating Greenbrook's operations, achieving positive operating cash flow and strengthening its balance sheet [16] Q&A Session Summary Question: Can you provide details on the CID investigation in Florida and Michigan? - Management confirmed that they are cooperating with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [36] Question: What are the profitability and patient monitoring differences for COMP360? - The treatment effect of COMP360 appears durable after one or two doses, and it will be administered under a REMS protocol similar to Spravato [40][42] Question: How did the $5 million payment to Perceptive affect cash position? - The payment did not come from restricted cash, and the company remains comfortable with its cash position despite projected Q1 cash burn [43][44] Question: Can you elaborate on the growth guidance for the clinic and standalone businesses? - Majority of growth in the clinic business is expected to come from volume, with Spravato growth anticipated to be significant in Q1 due to buy-and-bill impacts [50] Question: What are the integration requirements for the Compass collaboration? - The existing infrastructure for Spravato clinics will facilitate the integration of COMP360 treatments, with minimal additional updates needed [68]

Abeona Therapeutics (NasdaqCM:ABEO) Q4 2025 Earnings call March 17, 2026 08:30 AM ET Speaker7Good morning, everyone, and welcome to the Abeona Therapeutics full year 2025 results conference call. At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation. If anyone should require operator assistance during this conference, please press star zero on your phone keypad. Please note this conference is being recorded. During this call, we will re ...

Lifeway Foods (NasdaqGM:LWAY) Q4 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsJohn Mills - Managing Director of Investor RelationsJulie Smolyansky - CEO and PresidentJohn MillsGood morning. Welcome to Lifeway Foods' Fourth Quarter and Full Year 2025 Conference Call. On the call with me today is Julie Smolyansky, President and Chief Executive Officer. By now, everyone should have access to the press release that went out this morning. If you have not received the release, it is available ...

Weimob (SEHK:02013) H2 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsCao Yi - CFOSun Taoyong - Chairman of the Board and CEOYou Fengchun - Executive Director and PresidentConference Call ParticipantsLiao Yuan - AnalystXia Jun - AnalystOperatorThe event is for invited investors only. The audio recording transcript is for meeting for internal use by participants, not to be made public. Weimob Group has not authorized any media outlet to redistribute any content of this event. Any unauthori ...

China Literature (SEHK:00772) H2 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsCao Huayi - Non-executive DirectorHou Xiaonan - CEOHuang Yan - SVP and Executive DirectorJacky Xu - VP of FinanceMaggie Zhou - Head of Capital Markets and Investor RelationsNone - TranslatorConference Call ParticipantsGigi Zhou - Research AnalystJenny Yuan - Research AnalystMaggie Ye - Research AnalystXu Zhengzheng - VP and Equity AnalystOperatorGood evening, ladies and gentlemen. Welcome to China Literature's ...

Lifeway Foods (NasdaqGM:LWAY) Q4 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsJohn Mills - Managing Director of Investor RelationsJulie Smolyansky - CEO and PresidentJohn MillsGood morning. Welcome to Lifeway Foods' fourth quarter and full year 2025 conference call. On the call with me today is Julie Smolyansky, President and Chief Executive Officer. By now, everyone should have access to the press release that went out this morning. If you have not received the release, it is available ...